$KEQU

Kewaunee Scientific to Report Results for First Quarter Fiscal Year 2027

Kewaunee Scientific (NASDAQ: KEQU) will release its Q1 fiscal 2027 results on September 9, 2026, after market close. The company designs and manufactures laboratory and healthcare furniture, with operations in the U.S. and internationally. It also includes forward-looking statements about risks and uncertainties.

Original reporting
Published Aug 25, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Kewaunee Scientific to Report Results for First Quarter Fiscal Year 2027 — source image
Decision brief

The 30-second read

$KEQUNeutralLow
01

Why it matters

The filing is a routine earnings‑date announcement with no new financial metrics, offering limited trading insight.

02

Market read

Announcement of earnings release date; low immediate market impact.

03

What to watch

Potential hidden guidance or surprise elements may be hinted at in the press release, but none are disclosed.

Relevance 4/10Novelty 3/10Timing: after close Sep 9, 2026

Background

Kewaunee Scientific is a lab‑furniture manufacturer that regularly files quarterly results. This release follows its FY2026 year‑end.

Company-level read

Ticker impact

$KEQUNeutralHigh confidence
Context

Company announced it will release its FY2027 Q1 results on Sep 9, 2026 after market close.

Expected impact

Limited immediate impact; price may remain stable until the actual results are posted.

Evidence & confidence

No quantitative guidance or material event is disclosed, only the reporting schedule.

Market effects

Minimal; the announcement does not affect the broader lab‑furniture sector.

None; the news is company‑specific.

Low; no macro or cross‑border implications.

Counterpoint

Traders could ignore the date and focus on upcoming guidance trends rather than the reporting schedule.

Key entities

  • Kewaunee Scientific Corporation

    Laboratory furniture manufacturer (NASDAQ: KEQU).

Related articles

$KEQUMed

KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU): Results of Operations and Financial Condition

KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Kewaunee Scientific Reports Results for First Quarter of Fiscal Year 2027 Exchange: NASDAQ (KEQU) Contact: Donald T. Gardner III 704/871-3274 STATESVILLE, N.C. September 9, 2026 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its first qu

$KEQUMed

KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU): Results of Operations and Financial Condition

KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 prfy26q4earningsrelease.htm EX-99.1 Document Kewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter Exchange: NASDAQ (KEQU) Contact: Donald T. Gardner III 704/871-3274 STATESVILLE, N.C. June 23, 2026 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ

$ASMLMed

There Is One Thing ASML’s $400 Million Machine Still Cannot Do. AI Chips Keep Making It Worse.

ASML's $400M EUV lithography machines face limitations in producing large AI chips, requiring costly workarounds. ASML, TSMC, and partners are developing 12-inch photomasks for single-shot exposure, targeting 2031-2033. ASML's stock is up 112.6% year-over-year but faces near-term constraints, including export controls and capacity issues. Q2 2026 revenue grew 21.25% YoY to $10.65B, with operating income up 10.14%. ASML raised 2026 revenue guidance to EUR 43-45B, with a gross margin of 54-56%. An

$CRMHighAI 9/10

Jim Cramer on Salesforce (CRM): “It’s Been Very Strong of Late”

Jim Cramer highlighted Salesforce (CRM) on Mad Money, praising its AI platform Agentforce and strong recent performance. The company reported Q2 2027 revenue of $11.35B, up 11% YoY, and raised full-year guidance to $46.1B-$46.4B. CRM faces enterprise budget challenges and competition but shows strong AI adoption and cash flow.